DirectMeds review

DirectMeds connects patients with medical groups and third-party pharmacies; the platform itself does not practice medicine. Its catalog covers GLP-1 preparations, NAD+, sermorelin, glutathione and additional prescription categories. It remains outside the recommendations because its BPC-157 listing raises an unresolved routine commercial compounding concern. A physician-guided label does not by itself establish that an ingredient qualifies for that supply pathway, and an authorized research setting would be a different question. Confirm the exact preparation, clinical rationale and legal supply basis rather than treating the catalog as a blanket endorsement of each advertised medicine.

The public pricing page describes all-in semaglutide and tirzepatide offers, including clinical review, medication, supplies and shipping without a separate membership fee. Current help pages complicate a direct monthly comparison. The injectable semaglutide article describes a thirty-day bottle and a three-bottle starter commitment split into equal monthly payments. The tirzepatide help article shows a different amount from the main pricing page and even has a semaglutide heading. A promotion or plan difference may explain part of the discrepancy, but the reviewed material does not establish one binding quote for every order. Obtain the exact charge, commitment and formulation in the written confirmation.

The renewal cycle also needs resolution. General terms say the total subscription price is charged every thirty days, while a current monthly-prescription support article says billing and refill processing generally follow a twenty-eight-day cycle, subject to the medicine and review requirements. Other support wording describes monthly starter installments. These are different schedules. A supply label is not enough to choose between them, and a recurring charge may not correspond to a new shipment each time. Monthly comparison figures are withheld until the actual agreement resolves the period and amount. Do not infer a calendar-year payment count from the marketing word monthly.

The longevity pages require similar care. NAD+ and sermorelin material includes unrelated semaglutide wording, and current readable pages do not verify the older thirty- or ninety-day price ladders. Glutathione also needs a current product-specific renewal quote. A NAD+ page names ExperienceCare Pharmacy, but current support describes US 503A pharmacy fulfillment without assigning the facility for your order. The name on one product page should not become a promise about every prescription. Ask for the pharmacy name, address and actual label. Provider claims about energy, sleep, skin or healthy aging do not establish benefits for these specific preparations.

An online intake is followed by clinical review, and support says a short video consultation may be requested. Many reviews are completed within twenty-four hours, but timing varies. The shipping support article describes two to three business days of pharmacy processing, generally Monday through Thursday, before shipment. Temperature-controlled US orders use next-day air. That is different from guaranteed arrival one or two days after payment. Current support lists Mississippi and Louisiana as excluded; verify the particular treatment in your state rather than assuming an older exclusion list or a nationwide banner settles availability. Clinical eligibility and the dispensing facility’s authorization remain separate requirements.

The terms require turning off auto-refill at least forty-eight hours before the next processing date. Initial-order cancellation is an attempt within twenty-four hours only if the provider network has not received the order; it is not an unconditional cooling-off period. Medication already received is generally non-refundable, with stated exceptions for problems such as incorrect, damaged or unshipped products and denied prescriptions. Contact support promptly about an actual problem and review the applicable conditions. FDA’s cited warning letter separately criticized misleading equivalence presentations for compounded GLP-1s. It does not establish that the business is closed or that a particular later order has been reviewed or approved by FDA.